Ontology highlight
ABSTRACT: Purpose
Atezolizumab-bevacizumab (AB) is the established first-line systemic therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, the optimal second-line treatment for patients unresponsive to AB remains undefined.Patients and methods
This multicenter, retrospective study included patients with uHCC who underwent second-line treatment with lenvatinib (LEN) or sorafenib (SOR) after AB failure at two academic centers between June 2018 and November 2023. Treatment response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST. Propensity score matching (PSM) was employed to mitigate confounding bias.Results
A total of 123 were included in the final analysis, 56 patients received LEN, and 67 receive
SUBMITTER: Cheon J
PROVIDER: S-EPMC11775054 | biostudies-literature | 2025 Jan
REPOSITORIES: biostudies-literature